Remove Marketing Remove Packaging Remove Vaccine
article thumbnail

A Visual Guide to Gene Delivery

Codon

Companies weigh market size, reimbursement potential (the likelihood insurers or governments will pay for the therapy), and the level of existing competition before deciding which vector to use for their gene therapy. Its exact packaging size can vary by serotype, and there are now more than 20 antigenically distinct types of AAV.

article thumbnail

Levers for Biological Progress

Codon

Such models will, in turn, make it much easier to invent the sorts of platform tools that Amodei asserts “drive >50% of progress in biology,” such as CRISPR and mRNA vaccines, because the creation of these tools ultimately derive from a deeper understanding of how cells work.

DNA
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Uncertain Origins of Aspirin

Codon

NSAID Expansion: 1949 to present While it is seemingly impossible to find figures for aspirin consumption or production over time, it is clear that it took off after Bayer began marketing the drug in 1899. But it does matter whether people believe, for instance, that vaccination is the best way to prevent measles.

article thumbnail

Pfizer COVID vaccine under EMA review for younger teens

The Pharma Data

The European Medicines Agency (EMA) is evaluating an application submitted by Pfizer and BioNTech for use of their COVID-19 vaccine in children aged 12 to 15 years. . The vaccine has been authorized by the EU for use in people 16 years and up since December 2020. . Pfizer also shared antibody responses from the younger age group.

article thumbnail

AstraZeneca’s COVID-19 Vaccine Boasts Strong Results with Up to 90% Efficacy

The Pharma Data

As the Pfizer and BioNTech COVID-19 vaccine goes to regulators and the Moderna vaccine approaches the end of its Phase III trials, AstraZeneca and the University of Oxford announced high-level results from an interim analysis of their COVID-19 vaccine, AZD1222. The combined analysis showed average efficacy of 70%.

article thumbnail

Keeping tabs on Covid-19: FDA approves Veklury as first treatment for Covid-19 and Takeda and Moderna bring 50 million vaccines to Japan

The Pharma Data

Takeda and Moderna join forces to expand Covid-19 vaccine supply in Japan. A three-way agreement between Takeda , Moderna and the Government of Japan’s Ministry of Health Labour and Welfare (MHLW) plans to bring mRNA-1273, Moderna’s Covid-19 vaccine candidate, to Japan. Source link.

article thumbnail

From bench to batch: AAV manufacturing for the next-generation of gene therapies

BioPharma Drive: Drug Pricing

This results in more fully packaged and intact capsids, which are essential for reducing manufacturing costs per dose and enhancing the effectiveness of gene therapies. And the team must have the capability to offer regulatory support for each target market. By Jacob Bell • May 6, 2025 Keep up with the story.